| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910453434903321 |
|
|
Autore |
Kerns Edward Harvel |
|
|
Titolo |
Drug-like properties [[electronic resource] ] : concepts, structure design and methods : from ADME to toxicity optimization / / Edward H. Kerns and Li Di |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Amsterdam ; ; Boston, : Academic Press, c2008 |
|
|
|
|
|
|
|
ISBN |
|
1-281-76371-3 |
9786611763718 |
0-08-095162-7 |
0-08-055761-9 |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (549 p.) |
|
|
|
|
|
|
Altri autori (Persone) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Pharmaceutical chemistry |
Drugs - Structure-activity relationships |
Drug development |
Drugs - Design |
Electronic books. |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references (p. 492) and index. |
|
|
|
|
|
|
Nota di contenuto |
|
Front Cover; Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization; Copyright Page; Table of Contents; Preface; Dedication; Part 1 Introductory Concepts; Chapter 1 Introduction; Problems; References; Chapter 2 Advantages of Good Drug-like Properties; 2.1 Drug-like Properties Are an Integral Part of Drug Discovery; 2.1.1 Many Properties Are of Interest in Discovery; 2.1.2 Introduction to the Drug Discovery and Development Process; 2.1.3 Development Attrition is Reduced by Improving Drug Properties |
2.1.4 Poor Drug Properties Also Cause Discovery Inefficiencies2.1.5 Marginal Drug Properties Cause Inefficiencies During Development; 2.1.6 Poor Properties Can Cause Poor Discovery Research; 2.2 Changing Emphasis on Properties in Discovery; 2.3 Property Profiling in Discovery; 2.4 Drug-like Property Optimization in Discovery; Problems; References; Chapter 3 Barriers to Drug Exposure in Living Systems; 3.1 Introduction to Barriers; 3.2 Drug Dosing; 3.3 Barriers in the Mouth and |
|
|
|
|
|
|
|
|
|
|
|
Stomach; 3.4 Gastrointestinal Tract Barriers; 3.4.1 Permeation of the Gastrointestinal Cellular Membrane |
3.4.2 Passive Diffusion at the Molecular Level3.4.3 Metabolism in the Intestine; 3.4.4 Enzymatic Hydrolysis in the Intestine; 3.4.5 Absorption Enhancement in the Intestine; 3.5 Barriers in the Bloodstream; 3.5.1 Plasma Enzyme Hydrolysis; 3.5.2 Plasma Protein Binding; 3.5.3 Red Blood Cell Binding; 3.6 Barriers in the Liver; 3.6.1 Metabolism; 3.6.2 Biliary Excretion; 3.7 Barriers in the Kidney; 3.8 Blood-Tissue Barriers; 3.9 Tissue Distribution; 3.10 Consequences of Chirality on Barriers and Properties; 3.11 Overview of In Vivo Barriers; Problems; References; Part 2 Physicochemical Properties |
Chapter 4 Rules for Rapid Property Profiling from Structure4.1 Lipinski Rules; 4.2 Veber Rules; 4.3 Other Rules; 4.4 Application of Rules for Compound Assessment; Problems; References; Chapter 5 Lipophilicity; 5.1 Lipophilicity Fundamentals; 5.2 Lipophilicity Effects; 5.3 Lipophilicity Case Studies and Structure Modification; Problems; References; Chapter 6 pKa; 6.1 pKa Fundamentals; 6.2 pKa Effects; 6.3 pKa Case Studies; 6.4 Structure Modification Strategies for pKa; Problems; References; Chapter 7 Solubility; 7.1 Solubility Fundamentals |
7.1.1 Solubility Varies with Structure and Physical Conditions7.1.2 Dissolution Rate; 7.1.3 Structural Properties Affect Solubility; 7.1.4 Kinetic and Thermodynamic Solubility; 7.2 Effects of Solubility; 7.2.1 Low Solubility Limits Absorption and Causes Low Oral Bioavailability; 7.2.2 Good Solubility is Essential for IV Formulation; 7.2.3 Acceptance Criteria and Classifications for Solubility; 7.2.4 Molecular Properties for Solubility and Permeability Often are Opposed; 7.3 Effects of Physiology on Solubility and Absorption; 7.3.1 Physiology of the Gastrointestinal Tract |
7.3.2 Species Differences in Gastrointestinal Tract |
|
|
|
|
|
|
Sommario/riassunto |
|
Of the thousands of novel compounds that a drug discovery project team invents and that bind to the therapeutic target, typically only a fraction of these have sufficient ADME/Tox properties to become a drug product. Understanding ADME/Tox is critical for all drug researchers, owing to its increasing importance in advancing high quality candidates to clinical studies and the processes of drug discovery. If the properties are weak, the candidate will have a high risk of failure or be less desirable as a drug product. This book is a tool and resource for scientists engaged in, or preparing for, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2. |
Record Nr. |
UNINA9910466087303321 |
|
|
Autore |
Fisher Randall G. |
|
|
Titolo |
Moffet's pediatric infectious diseases : a problem-oriented approach / / Randall G. Fisher, MD, Professor of Pediatrics, Eastern Virginia Medical School, Director, Pediatric Infectious Diseases Division, Children's Specialty Group, PLLC, Children's Hospital of the King's Daughters, Norfolk, Virginia, Thomas G. Boyce, MD, MPH, Associate Professor of Pediatrics, Mayo Clinic College of Medicine, Division of Pediatric Infectious Diseases, Mayo Clinic, Rochester, Minnesota, Armando G. Correa, MD, Assistant Professor of Pediatrics, Baylor College of Medicine, Section of Academic General Pediatrics, Texas Children's Hospital, Houston, Texas |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Philadelphia : , : Wolters Kluwer, , [2017] |
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Edizione |
[Fifth edition.] |
|
|
|
|
|
Descrizione fisica |
|
1 online resource (ix, 683 pages) : illustrations (some color) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Communicable diseases in children |
Electronic books. |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references and index. |
|
|
|
|
|
|
Nota di contenuto |
|
Clinical decision making in pediatric infectious diseases -- Nose and throat syndromes -- Infectious mononucleosis and mononucucleosis-like syndromes -- Oral cavity and salivary gland syndromes -- Eye, ear, and sinus syndromes -- Face and neck syndromes -- Middle respiratory syndromes -- Pneumonia syndromes -- Neurologic syndromes -- Fever and sepsis syndromes -- Rash syndromes -- Gastrointestinal and intra-abdominal syndromes -- Hepatitis syndromes -- Urinary syndromes -- Genital syndromes -- Orthopedic syndromes -- Skin and soft-tissue syndromes -- Cardiovascular syndromes -- Congenital, perinatal, and neonatal syndromes -- HIV infection and AIDS -- Exposure problems -- Infections complicating chronic diseases -- The child with frequent, severe, or unusual infections : primary immunodeficiency syndromes. |
|
|
|
|
|
|
|
|
Sommario/riassunto |
|
This book provides step-by-step diagnosis and management using a signs and symptoms approach, with a patient-oriented structure for |
|
|
|
|
|
|
|
|
|
|
logical development of a differential diagnosis, evaluation and treatment plan, confirmation of the diagnosis and appropriate therapy. This edition includes new medications, new names of known pathogens, new practice guidelines, and extensive revisions to chapters on urinary syndromes, hepatitis syndromes, and HIV infection and AIDS. |
|
|
|
|
|
| |